Literature DB >> 25965570

Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.

Cara Lunn Shirai1, James N Ley1, Brian S White2, Sanghyun Kim1, Justin Tibbitts1, Jin Shao1, Matthew Ndonwi1, Brian Wadugu1, Eric J Duncavage3, Theresa Okeyo-Owuor1, Tuoen Liu1, Malachi Griffith4, Sean McGrath4, Vincent Magrini4, Robert S Fulton4, Catrina Fronick4, Michelle O'Laughlin4, Timothy A Graubert5, Matthew J Walter6.   

Abstract

Heterozygous somatic mutations in the spliceosome gene U2AF1 occur in ∼ 11% of patients with myelodysplastic syndromes (MDS), the most common adult myeloid malignancy. It is unclear how these mutations contribute to disease. We examined in vivo hematopoietic consequences of the most common U2AF1 mutation using a doxycycline-inducible transgenic mouse model. Mice expressing mutant U2AF1(S34F) display altered hematopoiesis and changes in pre-mRNA splicing in hematopoietic progenitor cells by whole transcriptome analysis (RNA-seq). Integration with human RNA-seq datasets determined that common mutant U2AF1-induced splicing alterations are enriched in RNA processing genes, ribosomal genes, and recurrently mutated MDS and acute myeloid leukemia-associated genes. These findings support the hypothesis that mutant U2AF1 alters downstream gene isoform expression, thereby contributing to abnormal hematopoiesis in patients with MDS.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25965570      PMCID: PMC4430854          DOI: 10.1016/j.ccell.2015.04.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  52 in total

1.  SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.

Authors:  V Visconte; H Makishima; A Jankowska; H Szpurka; F Traina; A Jerez; C O'Keefe; H J Rogers; M A Sekeres; J P Maciejewski; R V Tiu
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

2.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

3.  Frequent pathway mutations of splicing machinery in myelodysplasia.

Authors:  Kenichi Yoshida; Masashi Sanada; Yuichi Shiraishi; Daniel Nowak; Yasunobu Nagata; Ryo Yamamoto; Yusuke Sato; Aiko Sato-Otsubo; Ayana Kon; Masao Nagasaki; George Chalkidis; Yutaka Suzuki; Masashi Shiosaka; Ryoichiro Kawahata; Tomoyuki Yamaguchi; Makoto Otsu; Naoshi Obara; Mamiko Sakata-Yanagimoto; Ken Ishiyama; Hiraku Mori; Florian Nolte; Wolf-Karsten Hofmann; Shuichi Miyawaki; Sumio Sugano; Claudia Haferlach; H Phillip Koeffler; Lee-Yung Shih; Torsten Haferlach; Shigeru Chiba; Hiromitsu Nakauchi; Satoru Miyano; Seishi Ogawa
Journal:  Nature       Date:  2011-09-11       Impact factor: 49.962

4.  Clonal diversity of recurrently mutated genes in myelodysplastic syndromes.

Authors:  M J Walter; D Shen; J Shao; L Ding; B S White; C Kandoth; C A Miller; B Niu; M D McLellan; N D Dees; R Fulton; K Elliot; S Heath; M Grillot; P Westervelt; D C Link; J F DiPersio; E Mardis; T J Ley; R K Wilson; T A Graubert
Journal:  Leukemia       Date:  2013-02-27       Impact factor: 11.528

5.  Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms.

Authors:  Bartlomiej Przychodzen; Andres Jerez; Kathryn Guinta; Mikkael A Sekeres; Richard Padgett; Jaroslaw P Maciejewski; Hideki Makishima
Journal:  Blood       Date:  2013-06-17       Impact factor: 22.113

6.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

Authors:  E Papaemmanuil; M Cazzola; J Boultwood; L Malcovati; P Vyas; D Bowen; A Pellagatti; J S Wainscoat; E Hellstrom-Lindberg; C Gambacorti-Passerini; A L Godfrey; I Rapado; A Cvejic; R Rance; C McGee; P Ellis; L J Mudie; P J Stephens; S McLaren; C E Massie; P S Tarpey; I Varela; S Nik-Zainal; H R Davies; A Shlien; D Jones; K Raine; J Hinton; A P Butler; J W Teague; E J Baxter; J Score; A Galli; M G Della Porta; E Travaglino; M Groves; S Tauro; N C Munshi; K C Anderson; A El-Naggar; A Fischer; V Mustonen; A J Warren; N C P Cross; A R Green; P A Futreal; M R Stratton; P J Campbell
Journal:  N Engl J Med       Date:  2011-09-26       Impact factor: 91.245

7.  Differential expression analysis for sequence count data.

Authors:  Simon Anders; Wolfgang Huber
Journal:  Genome Biol       Date:  2010-10-27       Impact factor: 13.583

8.  Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.

Authors:  Timothy A Graubert; Dong Shen; Li Ding; Theresa Okeyo-Owuor; Cara L Lunn; Jin Shao; Kilannin Krysiak; Christopher C Harris; Daniel C Koboldt; David E Larson; Michael D McLellan; David J Dooling; Rachel M Abbott; Robert S Fulton; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Marcus Grillot; Jack Baty; Sharon Heath; John L Frater; Talat Nasim; Daniel C Link; Michael H Tomasson; Peter Westervelt; John F DiPersio; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Matthew J Walter
Journal:  Nat Genet       Date:  2011-12-11       Impact factor: 38.330

9.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

10.  Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.

Authors:  Omar Abdel-Wahab; Jie Gao; Mazhar Adli; Anwesha Dey; Thomas Trimarchi; Young Rock Chung; Cem Kuscu; Todd Hricik; Delphine Ndiaye-Lobry; Lindsay M Lafave; Richard Koche; Alan H Shih; Olga A Guryanova; Eunhee Kim; Sheng Li; Suveg Pandey; Joseph Y Shin; Leon Telis; Jinfeng Liu; Parva K Bhatt; Sebastien Monette; Xinyang Zhao; Christopher E Mason; Christopher Y Park; Bradley E Bernstein; Iannis Aifantis; Ross L Levine
Journal:  J Exp Med       Date:  2013-11-11       Impact factor: 14.307

View more
  126 in total

Review 1.  The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.

Authors:  Elisabeth Daguenet; Gwendal Dujardin; Juan Valcárcel
Journal:  EMBO Rep       Date:  2015-11-13       Impact factor: 8.807

Review 2.  Clonal hematopoiesis.

Authors:  Max Jan; Benjamin L Ebert; Siddhartha Jaiswal
Journal:  Semin Hematol       Date:  2016-10-20       Impact factor: 3.851

Review 3.  Altered RNA Processing in Cancer Pathogenesis and Therapy.

Authors:  Esther A Obeng; Connor Stewart; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2019-10-14       Impact factor: 39.397

Review 4.  Environmental influences on RNA processing: Biochemical, molecular and genetic regulators of cellular response.

Authors:  Athma A Pai; Francesca Luca
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-09-14       Impact factor: 9.957

5.  Haematological malignancies: Splicing the MDS genome.

Authors:  Gemma K Alderton
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

Review 6.  Therapeutic approaches to treat human spliceosomal diseases.

Authors:  Anthony B DeNicola; Yi Tang
Journal:  Curr Opin Biotechnol       Date:  2019-02-15       Impact factor: 9.740

7.  The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations.

Authors:  Liang Chen; Jia-Yu Chen; Yi-Jou Huang; Ying Gu; Jinsong Qiu; Hao Qian; Changwei Shao; Xuan Zhang; Jing Hu; Hairi Li; Shunmin He; Yu Zhou; Omar Abdel-Wahab; Dong-Er Zhang; Xiang-Dong Fu
Journal:  Mol Cell       Date:  2018-01-27       Impact factor: 17.970

8.  Modeling SF3B1 Mutations in Cancer: Advances, Challenges, and Opportunities.

Authors:  Daichi Inoue; Omar Abdel-Wahab
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

9.  Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.

Authors:  Esther A Obeng; Ryan J Chappell; Michael Seiler; Michelle C Chen; Dean R Campagna; Paul J Schmidt; Rebekka K Schneider; Allegra M Lord; Lili Wang; Rutendo G Gambe; Marie E McConkey; Abdullah M Ali; Azra Raza; Lihua Yu; Silvia Buonamici; Peter G Smith; Ann Mullally; Catherine J Wu; Mark D Fleming; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

Review 10.  Splicing factor gene mutations in hematologic malignancies.

Authors:  Borja Saez; Matthew J Walter; Timothy A Graubert
Journal:  Blood       Date:  2016-12-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.